Austrian biotech Marinomed has filed for insolvency as revenue expectations for the 2024 financial year could not be realized as anticipated.
Marinomed Starts Restructuring Proceedings As Debts Mount
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
More from Strategy
• By
Round up of the latest appointments: PAGB names vice presidents; Activ'Inside gets first US head; EMA elects management board chair.
• By
A round-up of the latest consumer health industry appointments: GSCF elects chair; Kenvue hires Northern Europe head; Barentz names chief commercial officer.
• By
Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.
• By
Alliance shareholders overwhelmingly back takeover by DBAY Advisors after improved offer values UK-based firm at £362m.
More from Ingredients & Safety
• By
UK food toxicity committee says substantial exceedances of the Acceptable Daily Intake of turmeric - such as through excessive supplement use - represents a potential health risk to humans.
• By
The Expert Panel for Cosmetic Ingredient Safety issued a revised tentative amended report for p-phenylenediamine and related ingredients during its 171st meeting.
• By
FSA now aims to send the first recommendations for the authorization of CBD novel food products to UK government ministers in 2025, according to its most recent board meeting. The agency is closely scrutinizing trace THC levels and is planning to ban use of CBD food products by under 18s.